clinical trial · NCT06531941
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
Hypoparathyroidism400 µg of MBX 2109 once-weekly by subcutaneous injection200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
brief summary
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
started
Oct 31, 2024
primary completion
May 27, 2027
completion
May 27, 2027
last updated
Oct 28, 2025
detailed description
This study is to investigate the long-term safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism. Additionally, the ability of MBX 2109 to maintain serum calcium levels within the normal range without the need for active vitamin D and to reduce elemental calcium supplements to ≤600 mg/day.
official title
An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol